A randomised trial investigating the effect on biomedical (PSA) control and survival of different durations of adjuvant androgen deprivation in association with definite radiation treatment for localised carcinoma of the prostate (RADAR)

Six months of hormone treatment improves the results of radiotherapy for men with early prostate cancer. This trial will determine if adding another 12 months of hormone treatment after radiotherapy is even better. Bones are often affected by prostate cancer and can also be damaged by prolonged hormone treatment. Bisphosphonates are drugs that make bones stronger. This trial will also determine if treatment with a bisphosphonate can help prevent these bone problems.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Final Accrual

1071

Closing Date of Accrual

2007

Trial Chairperson

Prof Jim Denham, Calvary Mater Newcastle, NSW

Trial Contact

Allison.Steigler@newcastle.edu.au

Clinical Trial Registration

Related Post

18 May, 2026

FASTRACK II trial finds emerging radiotherapy technique effectively controls kidney cancer

LATEST NEWS: 18 MAY 2026 A new non-invasive form

RTQA review paper
14 May, 2026

Review highlights vital need for RTQA in radiation therapy research

LATEST NEWS: 14 May 2026 The need for greater